Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials

• Main Authors: Kenneth B. Gordon (Author), Andrew Blauvelt (Author), Hervé Bachelez (Author), Laura C. Coates (Author), Filip E. Van den Bosch (Author), Blair Kaplan (Author), Willem Koetse (Author), Doug G. Ashley (Author), Ralph Lippe (Author), Ranjeeta Sinvhal (Author), Kim A. Papp (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Risankizumab has demonstrated a favourable safety profile in patients with psoriatic disease (moderate-to-severe psoriasis [PsO] and psoriatic arthritis [PsA]). We evaluated the long-term safety of risankizumab in psoriatic disease. Methods Long-term safety was evaluated by ana...